Home › GE Healthcare Files Supplemental New Drug Application For Its Own Manufacturing Of Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP)
 

Keywords :   


GE Healthcare Files Supplemental New Drug Application For Its Own Manufacturing Of Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP)

2013-01-15 13:50:00| drugdiscoveryonline News Articles

GE Healthcare recently announced that it has filed a supplemental new drug application (sNDA) that will allow the company to manufacture Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), within its own facility

Tags: application files drug manufacturing

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
06.10'Rightmove is my porn' - the addiction to online property search
06.10Eastern North Pacific Tropical Weather Outlook
06.10Atlantic Tropical Weather Outlook
05.10Tropical Storm Milton Public Advisory Number 2
05.10Hurricane Kirk Graphics
05.10Hurricane Kirk Forecast Discussion Number 26
05.10Tropical Storm Milton Graphics
05.10Hurricane Kirk Wind Speed Probabilities Number 26
More »